Every day, JDRF leverages the expertise and innovation of distinguished researchers from across the globe to support research for life-changing treatments and ultimately a cure for type 1 diabetes (T1D). Our mission aims to serve everybody with T1D—at all ages and stages of the disease. Please enjoy reading about some of the most recent advances […]
JDRF would love to hear from you about our first-ever digital annual report. Please share your feedback with us!
Technological advances and enhanced treatments over the past 40 years have led to major improvements in blood-glucose control for people with type 1 diabetes (T1D). More sophisticated tools, such as systems to automate some insulin delivery or glucose responsive insulin, could help to improve blood-glucose control. To this end, JDRF continues to lead in the […]
Carol Lurie, beloved wife, mother and grandmother, and a founder of JDRF, passed away on Friday, February 15th. Carol and her husband Erwin played a vital part in JDRF and its contributions to diabetes research, offering continual inspiration, guidance, and support working at the chapter, national, and international levels. We will miss her.
This year, we’re celebrating 42 years of milestones in T1D research, awareness, and advocacy. This annual report turns the spotlight on 42 of the unique people, programs, and signs of progress that compel people to join JDRF.
In December 2012, a study published in The Journal of the American Medical Association reported that people with type 1 diabetes (T1D) or who are at increased risk of developing the disease have smaller pancreases than people not at risk. Researchers studied pancreases from three groups of deceased donors: individuals with T1D, those with autoantibodies […]
The U.S. Food and Drug Administration (FDA) announced on November 9 the issuance of its final guidance for the development of artificial pancreas systems. The guidance incorporates nearly all of JDRF’s recommendations. This news represents a milestone victory for JDRF and the type 1 diabetes (T1D) community, as the technology is viewed by medical experts […]
For many people who have experienced diabetic macular edema (DME), the future looks a little clearer. On August 10, 2012, the U.S. Food and Drug Administration (FDA) approved use of the drug Lucentis for the treatment of DME. Developed by Genentech, Lucentis is the first and only FDA-approved medicine for the condition. Diabetic macular edema […]
The collaborative partnership of JDRF and The Leona M. and Harry B. Helmsley Charitable Trust has awarded a new grant in one of the most exciting and promising areas of type 1 diabetes (T1D) research. The $4.6-million grant, distributed over three years, will fund the beta cell encapsulation research of Camillo Ricordi, M.D., scientific director […]
Developing effective treatments for diabetic retinopathy is a key part of JDRF’s research goals. Until recently, the only treatment for diabetic macular edema was with lasers that often halted the worsening of the condition but did not improve a person’s eyesight. Now, however, a promising new treatment has emerged in the form of a drug called Lucentis (known generically as ranibizumab).